Comparative Benchmarking
In the context of the broader market, PHAR competes directly with industry leaders such as DBVT and AKTS. With a market capitalization of $1.16B, it holds a significant position in the sector. When comparing efficiency, PHAR's gross margin of N/A stands against DBVT's N/A and AKTS's 100.00%. Such benchmarking helps identify whether Pharming Group NV is trading at a premium or discount relative to its financial performance.
